| abstract |
The use of a carbostyril derivative of formula (1) where the broken line represents a single or double bond, or a pharmaceutically acceptable salt or solvate thereof, for the production of an effective drug in the treatment of central nervous system disorders associated with the 5-HT1A receptor subtype, selected from depression; cognitive impairment; autism; Down's Syndrome; attention deficit hyperactivity disorders (ADHD); neurodegenerative diseases selected from Alzheimer's disease and Parkinson's disease; obsessive compulsive disorders (OCD): sleep disorders; sexual dysfunction; Alcohol abuse; drug addiction; emesis; motion sickness; obesity; and migraine |